The fundamental purpose of Dunlop's is commonly used across conditions presenting with acute episodes marked by systemic imbalance. Its use is focused on clinical settings relevant in situations where short-term symptomatic assistance is needed.

The injection is indicated for the treatment of hypocalcaemia in target species.

---

Acute Intervention and Symptom Management

This medication is commonly used as an aid in treating acute electrolyte imbalances, specifically hypocalcaemia, which manifests as serious conditions like Milk Fever (Parturient Paresis) in cattle or Eclampsia in bitches. These are conditions associated with acute or disruptive episodes where symptoms may intensify temporarily. The medication is considered relevant for easing symptoms of increased neurological or muscular activity, including muscle tremors, tetanic spasms, and serious motor control issues like being unable to stand (recumbency).

The treatment may assist with maintaining functional stability during the metabolic crisis, which supports the patient during difficult episodes by easing distress. The treatment can offer supportive relief for cardiac stability and assists with maintaining functional stability in the circulatory system.

---

Quick Facts

Property	Description
Main Indication	Acute hypocalcaemia (Milk Fever, Eclampsia)
Symptom Relief	Muscle tremors, tetanic spasms, motor dysfunction, cardiac instability
Patient Groups	Periparturient cattle, bitches, small ruminants
Therapeutic Benefit	Supports maintenance of functional and systemic stability

Regulatory References

1. Summary of Product Characteristics - Veterinary Medicines Directorate

Who Can and Cannot Use Dunlop's?

This section describes the officially documented population eligibility rules for the use of Dunlop's (Calcium Borogluconate Injection), strictly based on government-approved labeling.

---

Eligibility and Absolute Contraindications

The medicine is classified for Veterinary Use Only and is absolutely contraindicated for humans.

The official label mandates that use is restricted to the target species: Cattle, Sheep, and Swine, primarily to treat acute hypocalcaemia like milk fever in adult, periparturient animals.

Use is contraindicated and the medicine must not be given to animals with the following pre-existing conditions, as defined in regulatory documents:

• Hypercalcaemia (elevated plasma calcium levels).
• Signs of cardiac distress or existing circulatory and cardiac disorders.
• Chronic kidney insufficiency or severe renal damage.
• Calcinosis or hypermagnesemia (when magnesium is present in the formulation).

---

Pregnancy Status and Restrictions

Dunlop's is generally considered safe for use during pregnancy and lactation in the target species. The label specifies that intravenous administration should be restricted to a veterinary professional, and caution is required when treating severely toxaemic animals.

The interaction profile for Dunlop's (Calcium Borogluconate Solution for Injection) is defined by officially documented physical incompatibilities and pharmacodynamic effects related to the rapidly available calcium ion.

Contraindicated and Restricted Combinations

Classification	Interacting Agents	Constraint
Formal Contraindication	Intravenous Ceftriaxone	Prohibited in neonates (28 days of age or younger) due to risk of life-threatening ceftriaxone-calcium precipitation.
Physical Incompatibility	Solutions containing Phosphate or Bicarbonate	Must not be mixed for parenteral administration as precipitation may occur.
Chemical Inactivation	Intravenous Minocycline	Must not be mixed as the calcium complexes the minocycline, rendering it inactive.
Timing-based Rule	Intravenous Ceftriaxone	Must not be administered simultaneously via a Y-site in any age group.

---

Pharmacodynamic and Exposure Interactions

Co-administration with specific medicinal products may alter cardiovascular function or calcium plasma concentrations:

• Cardiac Glycosides (e.g., Digoxin): Co-use may cause synergistic arrhythmias and increase cardiotoxic activities.
• Calcium Channel Blockers: Calcium administration may reduce the therapeutic response of these agents.
• Exposure Modifiers: Agents such as Vitamin D, Thiazide Diuretics, and Estrogen are documented to enhance the risk of hypercalcemia when used concurrently.

How Dunlop's Works

The mechanism of Dunlop's is defined by the rapid intravenous provision of the calcium ion ( Ca^2+) to establish normal plasma concentrations of the essential cation. Its action is focused on two essential, interrelated biological domains. The primary mechanism targets voltage-gated ion channels in nerve and muscle cell membranes. The increase in extracellular calcium ion concentration modulates the cell membrane potential, altering the threshold required for the cell to fire an electrical signal. This physiological change modulates the firing threshold in excitable tissues.

Simultaneously, calcium ions function as an essential co-factor for fundamental processes, binding to Troponin C to initiate Excitation-Contraction (E-C) Coupling in muscle fibers, including the heart. The mechanism also enables the function of enzymatic systems, such as the coagulation cascade (Factor IV). This action supports the establishment of coordinated muscle contractility and enables hemostatic function.

The specific composition, utilizing Boric Acid to form the soluble Calcium Borogluconate complex, chemically optimizes the solution to maximize the concentration of available Ca^2+ for rapid intravenous delivery, promoting the ready engagement of these stabilization and co-factor mechanisms.

How Dunlop's is Used: Administration Guidelines

Dunlop's (Calcium Borogluconate Solution for Injection) is administered focusing on rapid, acute intervention rather than long-term daily use. The usage is defined by specific administration routes, dosage volumes, and preparation procedures.

---

Routes and Dosing Patterns

The product is administered via parenteral injection to ensure swift systemic action. The routes are slow intravenous (IV) injection, which is essential for acute intervention, and subcutaneous (SC) injection, used as an alternative or follow-up.

Target Species	Administration Route	Dose Range	Frequency Pattern
Adult Cattle	Slow IV or SC Injection	200 to 500 mL	As-Needed Intermittent Use
Adult Sheep/Swine	Slow IV or SC Injection	50 to 125 mL	May be repeated after 8–12 hours

---

Administration Conditions

Specific procedural steps are followed to ensure proper use. The solution is warmed to body temperature (approximately 37 C) before it is injected. Intravenous administration is carried out slowly. If the subcutaneous route is utilized, the total volume is divided into multiple injection sites, and the sites are gently massaged post-injection to aid absorption.

The solution contains no antimicrobial preservatives, requiring the use of aseptic technique, and any unused solution remaining after the procedure is discarded. The medicine is utilized in periparturient animals, including during pregnancy and lactation.

Research Evidence: Overview of Studies for Calcium Borogluconate

Evidence for Use in Acute Hypocalcaemia (Milk Fever)

Evidence-based research exploring the Calcium Borogluconate injection was evaluated in Adult Dairy Cattle presenting with a severe, acute calcium deficit, commonly known as Milk Fever. The research landscape includes Randomized Controlled Trials (RCTs) and controlled field studies where the compound was evaluated for use in this high-risk population, particularly around the time of calving. Research examined this condition, which is relevant in trials assessing short-term symptom patterns related to temporary physiological imbalance to understand how the animal's systemic stability was monitored.

Research examined how quickly the mineral levels in the bloodstream shifted after the injection was administered. Findings describe patterns observed in the studies where an immediate and rapid increase in plasma calcium concentrations was measured shortly after the injection. Trials also explored the outcomes reflecting daily functioning or activity level, reporting the change in the animals’ ability to stand over 8 to 24 hours after administration.

Outcomes Monitored in Clinical Trials

The studies primarily monitored outcomes related to systemic or functional imbalance rather than long-term health. Researchers focused on monitoring the immediate biomarker shifts in the body. Specifically, studies explored the measurement of both the total and ionized forms of calcium in the plasma. Research also describes the concurrent monitoring of other associated minerals, such as magnesium and inorganic phosphorus, to observe the full electrolyte dynamics during the acute phase.

Long-Term Follow-up and Relapse Studies

Research provides context into the short-term recovery phase, but the evidence is limited regarding the long-term maintenance of mineral balance. Studies monitored the frequency of episodic or acute changes where the original condition recurred—a phenomenon known as rebound hypocalcaemia. Findings indicate that the injection's effects, which were observed across short time intervals, are generally short-lived. Trials exploring short-term symptom changes report how symptoms evolved in the observed populations during the first 24 to 48 hours, which is the period when animals are most susceptible to the condition recurring.

Research in Specific Groups

The clinical evaluation of the Calcium Borogluconate solution was studied for its use in high-risk Adult Dairy Cattle during the periparturient period. The results apply only to the populations studied, which means the evidence is predominantly specific to this group. Data for certain groups remain insufficient, and there is limited information to provide context regarding its use in other affected animals, such as sheep, goats, or bitches with eclampsia.

Key Limitations and Areas of Uncertainty

Research highlights what is known, but also what is still uncertain. Long-term effects are not fully established, and follow-up durations were limited in many of the key studies. The most significant limitation noted in the scientific literature is that the rapid, observed increase in calcium levels was associated with a relatively fast decline shortly after injection, sometimes leading to a return of the temporary physiological imbalance if further support is not provided.

Furthermore, many studies did not evaluate the calcium borogluconate component in isolation. The injection is often formulated and tested as a combination product (including minerals like magnesium or phosphorus). Therefore, evidence derived from these settings suggests that isolating the specific contribution of the calcium borogluconate alone to all observed patterns is difficult because the data primarily describe combination products.

Key Studies & References

1. Milk fever: new approaches to treatment and control (Proceedings) - DVM360 (Discussing quick calcium decline/relapse and combination products)
2. SOLVET CALCIUM BOROGLUCONATE 23% INJECTION (Regulatory and indication information)

Common questions about Dunlop's (FAQ)

---

Q: How quickly does Dunlop's typically start to have an effect?

Dunlop's is administered intravenously (IV) to ensure the calcium ion is introduced into the bloodstream very quickly. Official product information indicates this route results in an immediate and rapid increase in plasma calcium concentrations shortly after the injection.

---

Q: What is the longest period of time people typically use Dunlop's for?

The medicine is classified for acute and intermittent use to quickly resolve a severe calcium deficit, not for continuous, long-term treatment. Official administration instructions define the dosing pattern as 'as-needed.' Studies indicate the effects observed are generally short-lived.

---

Q: What are the most commonly reported side effects in research for Dunlop's?

For the local administration site (subcutaneous route), official regulatory documents cite temporary swelling at the injection site as the most frequent reaction. For systemic effects, associated signs described in official sources may include initial bradycardia (slowing of the heart rate), agitation, and muscle tremors.

---

Q: Is it true that taking Dunlop's with food changes how much of the drug gets absorbed?

No. The product is a Solution for Injection administered directly into the body's circulation (parenteral route), which means it bypasses the digestive system entirely. Therefore, restrictions related to food or drink intake are not a factor for its use.

---

Q: How long does Dunlop's stay in your system after the last dose?

Official research indicates that the therapeutic effects of the injection are generally short-lived. It is documented that plasma calcium levels often show a fast decline shortly after the injection, sometimes leading to a return of the deficiency pattern.

---

Q: Is Dunlop's the same kind of medicine as [similar drug name]?

Dunlop's is officially classified by regulatory bodies as a Mineral Supplement, specifically a concentrated source of the calcium ion. Other products that share the same core pharmacological classification are similar because they aim to achieve the same therapeutic goal. However, the specific composition or use conditions may differ among various formulations.

---

Q: Why is Dunlop's often described as a 'first-line' treatment?

Official regulatory guidance recognizes this injectable formulation as a critical intervention tool for addressing acute calcium deficits. Because its formulation allows for the rapid delivery of calcium, its use is recognized as a critical intervention for rapid stabilization.

---

Q: Are there any long-term side effects associated with Dunlop's use?

Regulatory-cited research notes that the evidence is limited regarding the long-term maintenance of mineral balance following use. Studies predominantly focus on the immediate acute phase of treatment, and official reports indicate that long-term effects are not fully established due to limited follow-up durations in the key studies.

---

Q: What is the potential interaction between Dunlop's and caffeine?

Research studies have examined calcium borogluconate in formulations that include caffeine. These formulations are used because the caffeine component can promote neuro-muscular stimulation during acute treatment for the primary condition.

---

Q: Are there any specific foods or drinks that should be avoided while taking Dunlop's?

Because this medicine is administered by injection (parenteral route), which bypasses the digestive tract, food or drink restrictions related to digestive absorption are generally not a factor.

---

Q: What is the evidence for Dunlop's working in the long term?

Official research focuses on short-term symptom patterns and recovery within the first 24 to 48 hours following injection. The evidence is limited regarding the long-term maintenance of mineral balance, with studies focusing mainly on the immediate, acute stabilization period.

---

Q: Are the research studies on Dunlop's considered reliable and extensive?

The research landscape supporting the use of Dunlop's includes Randomized Controlled Trials (RCTs) and controlled field studies, which are considered reliable research methods. However, the scientific literature notes that the injection is often studied as a combination product with other minerals, making it difficult to isolate the specific contribution of the calcium borogluconate component alone.

---

Q: What should I expect if I miss a dose of Dunlop's?

The medicine is administered on an 'As-Needed Intermittent' basis for acute, critical conditions. Since the medicine is used for an acute, 'As-Needed Intermittent' treatment, the dosing schedule is based on the patient's immediate need. Official labels state that a dose may be repeated after several hours if required.

---

Q: Is there a risk of becoming dependent on Dunlop's over time?

Dunlop's is classified as a Mineral Supplement used for the acute replenishment of an essential electrolyte. Consistent with its pharmacological class and defined purpose, regulatory documents do not list dependence, addiction, or abuse potential as associated risks with the administration of this medicine.

---

Q: Is it normal for the color of the pill/tablet for Dunlop's to vary?

Dunlop's is a Sterile Solution for Injection, not a pill or tablet. It is classified as an aqueous solution. Official product descriptions state that the liquid solution should be clear, ranging from colorless to pale yellow when stored correctly.

---

Q: Does Dunlop's affect blood pressure or heart rate?

Yes, regulatory documents note effects on the cardiovascular system. Official safety information warns that rapid intravenous administration may result in serious adverse reactions including cardiac arrhythmias and heart block. Associated signs may also include initial bradycardia (slowing of the heart rate).

---

Q: Why do official sources list so many potential side effects for Dunlop's?

Regulatory documents and official product labeling are required to be comprehensive and uncertainty-respecting. They must list all known or potential adverse effects observed during studies or post-market surveillance. This ensures that users are informed of all possible risks associated with the product, regardless of how frequently they may occur.

---

Q: Is Dunlop's available as a generic medicine?

Yes. Regulatory databases list the active ingredient, Calcium Borogluconate, under multiple distinct brand names from various manufacturers. This indicates that therapeutically equivalent generic versions are available alongside the original brand name formulations.

---

Q: Why does Dunlop's come in different dosage strengths?

The rationale for different strengths is primarily related to chemical optimization. The variations ensure a high concentration of the available calcium ion can be delivered rapidly. This high concentration is essential for achieving the acute therapeutic action needed during critical mineral loss scenarios.

---

Q: Does Dunlop's have a potential for causing allergic reactions?

As with any medicinal product, the potential for an adverse reaction, including hypersensitivity, exists. Safety documents include general first-aid procedures for handling potential allergic reactions.

---

Q: Is Dunlop's used to treat symptoms, or the underlying condition?

The medicine's general purpose is the rapid replenishment of plasma calcium levels, meaning it directly treats the underlying physiological disturbance—the acute calcium deficit. By doing so, it supports and stabilizes critical biological processes like muscle contraction and cardiac stability, which indirectly relieves the symptoms of the deficit.

---

Q: What does the term 'evidence indicates' mean in relation to Dunlop's effectiveness?

This phrase is used in medical content to signal that a claim is grounded in verifiable facts obtained from the available research studies, such as Randomized Controlled Trials (RCTs). It is used to ensure the information is neutral and verifiable, emphasizing that the statement is supported by, but limited to, the current body of scientific evidence.

---

Q: Do children or adolescents have specific safety concerns with Dunlop's?

Official labels include a formal contraindication (restriction) regarding the use of the product in very young patients. It is prohibited in neonates (28 days of age or younger) due to the risk of life-threatening precipitation when combined with another specific antibiotic, Ceftriaxone.

---

Q: What if a known side effect of Dunlop's is already a symptom of my condition?

Official regulatory documents warn against using the product when certain conditions are already present. This includes existing cardiac disorders or signs of cardiac distress, due to the risk that the administration of the drug could potentially exacerbate these existing effects.

---

Q: Why are there different brand names for the same drug as Dunlop's?

Different brand names exist for products that contain the same active ingredient, Calcium Borogluconate, due to the licensing and marketing efforts of various manufacturers. Regulatory agencies define these as therapeutically equivalent generic and brand-name formulations, ensuring they meet the same standards.

How to Store and Dispose of Dunlop's?

The storage and disposal of Calcium Borogluconate Solution for Injection must adhere strictly to official regulatory requirements to maintain product stability and safety.

Storage Conditions

• Temperature: The solution must be stored below 25, C and must be protected from freezing and excessive heat.
• Light Protection: The product must be protected from light.
• Child Safety: The medicine must always be stored out of reach of children.

Handling and Stability

• The injection is classified for single use only in most regulatory documents. Any product remaining in the vial after the dose is withdrawn must be discarded to prevent quality loss.

Disposal

• All unused or expired medicine and waste materials derived from the product must be disposed of in accordance with local requirements for pharmaceutical waste.